Indonesia

Population 2018: 268 million

Tuberculosis profile

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>845 (770–923)</td>
<td>316 (288–345)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>21 (8.9–38)</td>
<td>7.9 (3.3–14)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceºº</td>
<td>24 (17–32)</td>
<td>8.8 (6.2–12)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>98 (67–98)</td>
<td>35 (33–37)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>5.3 (2.1–9.8)</td>
<td>2 (0.79–3.7)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 2.4% (1.8–3.3)
- Previously treated cases: 13% (9–18)

TB case notifications, 2018

- Total new and relapse: 563,879
  - % tested with rapid diagnostics at time of diagnosis: 12%
  - % with known HIV status: 37%
  - % pulmonary: 88%
  - % bacteriologically confirmedººº: 50%
  - % children aged 0–14 years: 11%
  - % women: 37%
  - % men: 52%
- Total cases notified: 570,289

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 67% (61–73)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 12% (10–13)
- TB/HIV care in new and relapse TB patients, 2018
- Patients with known HIV status who are HIV-positive:
  - on antiretroviral therapy: 4,082 (40%)
- Drug-resistant TB care, 2018
  - % of bacteriologically confirmed TB cases tested for rifampicin resistance ººº:
    - New cases: 33%
    - Previously treated cases: 127%
- Laboratory-confirmed cases*: MDR/RR-TB: 9,038, XDR-TB: 80
- Patients started on treatment**: MDR/RR-TB: 4,194, XDR-TB: 59
- MDR/RR-TB cases tested for resistance to second-line drugs: 2,526

Treatment success rate and cohort size

- New and relapse cases registered in 2017: 86% (425,819)
- Previously treated cases, excluding relapse, registered in 2017: 73% (4,934)
- HIV-positive TB cases registered in 2017: 69% (7,966)
- MDR/RR-TB cases started on second-line treatment in 2016: 48% (1,905)
- XDR-TB cases started on second-line treatment in 2016: 21% (61)

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 10%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 10% (9.3–11)

TB financing, 2019

- National TB budget (US$ millions): 366
  - Funding source: 30% domestic, 13% international, 57% unfunded

º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-02-23

Data: www.who.int/tb/data